Difficulty: Medium
Average Score: 63%
Practice
Five patients with cancer and/or inflammatory disease are being considered for treatment with single agent methotrexate therapy intravenously. Which of the following patients would be expected to have the greatest objective clinical response to therapy?
Correct answer
B
Rationale
In this scenario, the correct answer is option B, the 34-year-old man with choriocarcinoma of the testicle, who would be expected to have the greatest objective clinical response to single-agent methotrexate therapy intravenously. Choriocarcinoma is a highly chemosensitive tumor, and methotrexate is particularly effective in treating trophoblastic tumors like choriocarcinoma due to their high proliferation rate.
Option A, the 24-year-old man with Crohn's disease, is less likely to have a significant clinical response to methotrexate as it is often used in lower doses and via different routes for autoimmune diseases like Crohn's.
Option C, the 39-year-old woman with breast cancer and lymphatic metastasis, and option D, the 45-year-old woman with breast cancer and no evidence of lymphatic spread, are unlikely to benefit significantly from single-agent methotrexate therapy as it is not typically the first-line treatment for breast cancer, especially in the presence of metastasis.
Educationally, understanding the specific indications and efficacy of chemotherapy drugs like methotrexate in different types of cancers is crucial for healthcare professionals making treatment decisions. It highlights the importance of tailored therapy based on the tumor type and its responsiveness to specific agents, ultimately impacting patient outcomes and quality of life.
Option A, the 24-year-old man with Crohn's disease, is less likely to have a significant clinical response to methotrexate as it is often used in lower doses and via different routes for autoimmune diseases like Crohn's.
Option C, the 39-year-old woman with breast cancer and lymphatic metastasis, and option D, the 45-year-old woman with breast cancer and no evidence of lymphatic spread, are unlikely to benefit significantly from single-agent methotrexate therapy as it is not typically the first-line treatment for breast cancer, especially in the presence of metastasis.
Educationally, understanding the specific indications and efficacy of chemotherapy drugs like methotrexate in different types of cancers is crucial for healthcare professionals making treatment decisions. It highlights the importance of tailored therapy based on the tumor type and its responsiveness to specific agents, ultimately impacting patient outcomes and quality of life.